AR115643A1 - PEPTIDES RESTRICTED BY A * 03 FOR USE IN IMMUNOTHERAPY AGAINST CANCER AND RELATED METHODS - Google Patents
PEPTIDES RESTRICTED BY A * 03 FOR USE IN IMMUNOTHERAPY AGAINST CANCER AND RELATED METHODSInfo
- Publication number
- AR115643A1 AR115643A1 ARP190101807A ARP190101807A AR115643A1 AR 115643 A1 AR115643 A1 AR 115643A1 AR P190101807 A ARP190101807 A AR P190101807A AR P190101807 A ARP190101807 A AR P190101807A AR 115643 A1 AR115643 A1 AR 115643A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- peptides
- peptide
- refers
- molecules
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000037029 cross reaction Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente se refiere a la inmunoterapia contra el cáncer. La presente se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán trasferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión. Reivindicación 1: Péptido que comprende una secuencia de aminoácidos seleccionada entre el grupo consistente en la SEQ ID Nº 1 a la SEQ ID Nº 226 y las SEQ ID Nº 252 a SEQ ID Nº 272, y secuencias variantes de las mismas que son como mínimo homólogas en un 88% a las SEQ ID Nº 1 a la SEQ ID Nº 226 y las SEQ ID Nº 252 a SEQ ID Nº 272, y en que dicha variante se une a una o varias moléculas del complejo mayor de histocompatibilidad (MHC) y/o induce la reacción cruzada de linfocitos T con dicho péptido variante; y una sal farmacéuticamente aceptable del mismo, en que dicho péptido tiene menos de 30 aminoácidos de longitud.This refers to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, this refers to immunotherapy against cancer. The present also refers to peptide epitopes for tumor-associated T lymphocytes, alone or in combination with other tumor-associated peptides that, for example, can serve as active pharmaceutical ingredients in vaccine compositions intended to stimulate antitumor immune responses, or to stimulate ex vivo. T lymphocytes that will later be transferred to patients. Peptides bound to major histocompatibility complex (MHC) molecules, or peptides as such, can also be targets of antibodies, soluble T cell receptors, and other binding molecules. Claim 1: Peptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 226 and SEQ ID No. 252 to SEQ ID No. 272, and variant sequences thereof that are at least homologous 88% to SEQ ID No. 1 to SEQ ID No. 226 and SEQ ID No. 252 to SEQ ID No. 272, and in which said variant binds to one or more molecules of the major histocompatibility complex (MHC) and / or induces T lymphocyte cross-reaction with said variant peptide; and a pharmaceutically acceptable salt thereof, wherein said peptide is less than 30 amino acids in length.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102018115865.3A DE102018115865A1 (en) | 2018-06-29 | 2018-06-29 | A * 03 restricted peptides for use in cancer immunotherapy and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115643A1 true AR115643A1 (en) | 2021-02-10 |
Family
ID=69320236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101807A AR115643A1 (en) | 2018-06-29 | 2019-06-28 | PEPTIDES RESTRICTED BY A * 03 FOR USE IN IMMUNOTHERAPY AGAINST CANCER AND RELATED METHODS |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR115643A1 (en) |
| DE (1) | DE102018115865A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| WO2017089786A1 (en) * | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
-
2018
- 2018-06-29 DE DE102018115865.3A patent/DE102018115865A1/en not_active Withdrawn
-
2019
- 2019-06-28 AR ARP190101807A patent/AR115643A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE102018115865A1 (en) | 2020-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121588A2 (en) | NEW PEPTIDES AND A NEW PEPTIDE COMBINATION FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER TYPES OF CANCER | |
| PE20181490A1 (en) | TREATMENTS AGAINST CANCER OF THE UTERUS | |
| CL2020002387A1 (en) | Peptides (seq id no: 39) and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancer (application divisional no. 202002123) | |
| PE20240645A1 (en) | IMMUNOGENIC PEPTIDE DERIVED FROM HUMAN LEUKOCYTE ANTIGEN (HLA) MOLECULES AS A BIOMARKER IN THE IMMUNOTHERAPY OF VARIOUS TUMORS | |
| CL2021002459A1 (en) | Peptides and peptide combinations for use in cancer immunotherapy (divisional of application no. 201902093) | |
| PE20240778A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | |
| PE20181897A1 (en) | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER TYPES OF CANCER | |
| CO2021004270A2 (en) | B * 44 Restricted Peptides for Use in Cancer Immunotherapy and Related Methods | |
| CL2020002949A1 (en) | Peptides and peptide combinations for use in immunotherapy against leukemia and other cancers (divisional application 201902878) | |
| CO2021003404A2 (en) | Immunotherapy with a * 01-restricted peptides and a combination of anticancer peptides and related methods | |
| PE20231506A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SARS-COV-2 INFECTION (COVID-19) | |
| CL2022003381A1 (en) | a*03-restricted peptides, use in cancer immunotherapy and related methods (split application 202003371) | |
| CL2020002935A1 (en) | Peptides for use in cancer immunotherapy | |
| CL2020001563A1 (en) | Peptides (seq id no. 64, seq id no. 2 to seq id no. 63, seq id no. 65 to seq id no. 118, and seq id no. 120 to seq id no. 149), combinations of peptides and cells for use in immunotherapy against urinary bladder cancer and other cancers. (divisional request 201802360) | |
| AR114737A1 (en) | IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO A * 01 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS | |
| AR115643A1 (en) | PEPTIDES RESTRICTED BY A * 03 FOR USE IN IMMUNOTHERAPY AGAINST CANCER AND RELATED METHODS | |
| CL2021001525A1 (en) | Novel peptides and novel peptide combinations as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma, as well as other types of cancer (divisional application no. 201803293) | |
| CL2020002858A1 (en) | New peptides (seq id no: 203) and new peptide combinations for use in immunotherapy against non-Hodgkin's lymphoma (NHL) and other cancers (divisional application no. 201802096). | |
| CL2020002173A1 (en) | New peptide selected from seq id no: 3 and 4, and new peptide combinations for use in immunotherapy against acute myeloid leukemia (AML) and other types of cancer. (divisional request 201802827) | |
| AR105011A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS TO CREATE SUPPORTS FOR USE AGAINST CANCER CANCER AND OTHER TYPES OF CANCER | |
| AR103962A1 (en) | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCER OF PANCREAS AND OTHER TYPES OF CANCER | |
| AR106499A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST MICROCYTIC LUNG CANCER AND OTHER TYPES OF CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |